Eleanor M. Wigmore

Cambridge, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 24 publications

Targeting the chromatin modifying enzyme, KDM5C, enhances AKT inhibition response in ER+ breast cancer.

Targeting the chromatin modifying enzyme, KDM5C, enhances AKT inhibition response in ER+ breast cancer.

Journal: Molecular cancer therapeutics

Published: August 22, 2025

The interplay between FOXO3 and FOXM1 influences sensitivity to AKT inhibition in PIK3CA and PIK3CA/PTEN altered estrogen receptor positive breast cancer.

The interplay between FOXO3 and FOXM1 influences sensitivity to AKT inhibition in PIK3CA and PIK3CA/PTEN altered estrogen receptor positive breast cancer.

Journal: NPJ breast cancer

Published: September 17, 2024

Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.

Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.

Journal: NPJ breast cancer

Published: September 19, 2023

Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.

Author Correction: Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.

Journal: NPJ breast cancer

Published: August 18, 2023

Effects of protein-coding variants on blood metabolite measurements and clinical biomarkers in the UK Biobank.

Effects of protein-coding variants on blood metabolite measurements and clinical biomarkers in the UK Biobank.

Journal: American journal of human genetics

Published: November 21, 2022

Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.

Combining the AKT inhibitor capivasertib and SERD fulvestrant is effective in palbociclib-resistant ER+ breast cancer preclinical models.

Journal: NPJ breast cancer

Published: October 19, 2022

AZD4625 is a Potent and Selective Inhibitor of KRASG12C.

AZD4625 is a Potent and Selective Inhibitor of KRASG12C.

Journal: Molecular cancer therapeutics

Published: April 05, 2022

Integrated analyses of growth differentiation factor-15 concentration and cardiometabolic diseases in humans.

Integrated analyses of growth differentiation factor-15 concentration and cardiometabolic diseases in humans.

Journal: eLife

Published: December 10, 2021

Identifying the Common Genetic Basis of Antidepressant Response.

Identifying the Common Genetic Basis of Antidepressant Response.

Journal: Biological psychiatry global open science

Published: April 29, 2021

Author Correction: Genome-wide association study of depression phenotypes in UK Biobank identifies variants in excitatory synaptic pathways.

Author Correction: Genome-wide association study of depression phenotypes in UK Biobank identifies variants in excitatory synaptic pathways.

Journal: Nature communications

Published: March 26, 2021

Identification of a missense variant in SPDL1 associated with idiopathic pulmonary fibrosis.

Identification of a missense variant in SPDL1 associated with idiopathic pulmonary fibrosis.

Journal: Communications biology

Published: September 10, 2020

Pharmaco-epidemiology of antidepressant exposure in a UK cohort record-linkage study.

Pharmaco-epidemiology of antidepressant exposure in a UK cohort record-linkage study.

Journal: Journal of psychopharmacology (Oxford, England)

Published: February 28, 2019

Showing 1-12 of 24

Last Updated: 09/26/2026